Pharma 60: Mycobacterial Disease - Winning a War of Attrition

This episode explores tuberculosis, non-tuberculous mycobacterial disease (including MAC), and leprosy as the pharmacology of endurance. Mycobacteria grow slowly, hide within host cells, and possess formidable cell walls-forcing therapy to be prolonged, multi-drug, and meticulously coordinated. We examine cell wall synthesis inhibition, RNA polymerase targeting, energy metabolism disruption, and intracellular penetration to understand why monotherapy fails and adherence saves lives. The clinical emphasis is long-horizon thinking: resistance prevention, toxicity surveillance, and public-health responsibility.Key takeaways to secure mastery:* Biological stubbornness: slow growth, dormancy, and intracellular sanctuaries.* Combination necessity: why multiple drugs protect efficacy and prevent resistance.* Duration logic: months of therapy as a pharmacological requirement, not excess.* Toxicity vigilance: hepatotoxicity, neuropathy, optic effects, and interactions.* Systems view: adherence, directly observed therapy, and population impact. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe